535 related articles for article (PubMed ID: 25819732)
1. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma.
Harimoto N; Yoshida Y; Kurihara T; Takeishi K; Itoh S; Harada N; Tsujita E; Yamashita YI; Uchiyama H; Soejima Y; Ikegami T; Yoshizumi T; Kawanaka H; Ikeda T; Shirabe K; Saeki H; Oki E; Kimura Y; Maehara Y
Transplant Proc; 2015 Apr; 47(3):703-4. PubMed ID: 25819732
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
[TBL] [Abstract][Full Text] [Related]
3. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma.
Shindoh J; Sugawara Y; Nagata R; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Tanaka T; Kokudo N
Transpl Int; 2014 Apr; 27(4):391-8. PubMed ID: 24472068
[TBL] [Abstract][Full Text] [Related]
4. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.
Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y
Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789
[TBL] [Abstract][Full Text] [Related]
5. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years.
Uchiyama H; Itoh S; Yoshizumi T; Ikegami T; Harimoto N; Soejima Y; Harada N; Morita K; Toshima T; Motomura T; Maehara Y
HPB (Oxford); 2017 Dec; 19(12):1082-1090. PubMed ID: 28888776
[TBL] [Abstract][Full Text] [Related]
6. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
7. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value.
Shimada M; Yonemura Y; Ijichi H; Harada N; Shiotani S; Ninomiya M; Terashi T; Yoshizumi T; Soejima Y; Maehara Y
Transplant Proc; 2005 Mar; 37(2):1177-9. PubMed ID: 15848661
[TBL] [Abstract][Full Text] [Related]
8. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
Lee KW; Yi NJ; Suh KS
Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
[TBL] [Abstract][Full Text] [Related]
9. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
10. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
12. Living donor liver transplantation for hepatocellular carcinoma.
Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
Gao F; Zhu HK; Zhu YB; Shan QN; Ling Q; Wei XY; Xie HY; Zhou L; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):371-7. PubMed ID: 27498576
[TBL] [Abstract][Full Text] [Related]
14. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations.
Hwang S; Lee SG; Joh JW; Suh KS; Kim DG
Liver Transpl; 2005 Oct; 11(10):1265-72. PubMed ID: 16184545
[TBL] [Abstract][Full Text] [Related]
15. Two-step selection criteria for living donor liver transplantation in patients with hepatocellular carcinoma.
Yoshizumi T; Ikegami T; Toshima T; Harimoto N; Uchiyama H; Soejima Y; Yamashita Y; Shirabe K; Maehara Y
Transplant Proc; 2013 Nov; 45(9):3310-3. PubMed ID: 24182807
[TBL] [Abstract][Full Text] [Related]
16. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.
Kaibori M; Matsui Y; Yanagida H; Yokoigawa N; Kwon AH; Kamiyama Y
World J Surg; 2004 Jul; 28(7):702-7. PubMed ID: 15185000
[TBL] [Abstract][Full Text] [Related]
17. HCC in living donor liver transplantation: can we expand the Milan criteria?
Kwon CH; Kim DJ; Han YS; Park JB; Choi GS; Kim SJ; Joh JW; Lee SK
Dig Dis; 2007; 25(4):313-9. PubMed ID: 17960066
[TBL] [Abstract][Full Text] [Related]
18. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma.
Soejima Y; Taketomi A; Yoshizumi T; Uchiyama H; Aishima S; Terashi T; Shimada M; Maehara Y
Transplantation; 2007 Apr; 83(7):893-9. PubMed ID: 17460559
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma.
Ninomiya M; Shirabe K; Facciuto ME; Schwartz ME; Florman SS; Yoshizumi T; Harimoto N; Ikegami T; Uchiyama H; Maehara Y
J Am Coll Surg; 2015 Mar; 220(3):297-304.e3. PubMed ID: 25617912
[TBL] [Abstract][Full Text] [Related]
20. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
